重组人腺病毒注射液对胃癌细胞SGC-7901的细胞周期的影响  

Effect of recombinant adenovirs encoding human p53 on cell cycle of gastric cancer SGC-7901 cells

作　　者：崔荣花[1] 王美清[1] 毛山山[1] 程小珍[1] 元建华[1] 李兴[1] CUIRong-hua;WANG Mei-qing;MAO Shan-shan;CHENG Xiao-zhen;YUAN Jian-hua;LI Xing(Department of Oncology,Affiliated Haikou Hospital of Xiangya MedicalCollege,CentralSouthUniversity,Haikou570208,HainanProvince,China)

机构地区：[1]中南大学湘雅医学院附属海口医院肿瘤科,海南海口570208

出　　处：《中国临床药理学杂志》2020年第18期2829-2831,2838,共4页The Chinese Journal of Clinical Pharmacology

基　　金：海南省卫生厅基金资助项目(琼卫2012LX-16)。

摘　　要：目的研究重组人p53腺病毒注射液(recombinant adenovirs encoding human p53,rAd-p53)单独及联合顺铂(cisplatin,DDP)用药后对胃癌SGC-7901细胞周期的影响。方法人胃癌SGC-7901细胞随机分为对照组(0.9%NaCl)和rAd-p53低、高剂量组(5×10^8,5×10^10 vp·mL^-1),DDP组(2.5 mg·L^-1),低、高剂量联合组(5×10^8 vp·mL^-1+2.5 mg·L^-1、5×10^10 vp·mL^-1+2.5 mg·L^-1),给药48 h后,用流式细胞术检测细胞周期,用免疫组化法检测KAI1/CD82、p53蛋白的表达情况。结果对照组,rAd-p53低、高剂量组,DDP组,低、高剂量联合组细胞停滞在G0/G1期比例分别为(32.07±1.45)%,(40.18±1.36)%,(44.64±1.27)%,(43.41±2.08)%,(49.56±1.12)%,(54.72±6.07)%;KAI1/CD82蛋白表达量分别为(24.60±3.73)%,(32.73±3.15)%,(35.50±2.27)%,(36.13±3.77)%,(48.67±4.70)%,(51.70±2.55)%;p53蛋白表达量分别为(14.60±3.63)%,(43.30±2.35)%,(46.40±1.80)%,(49.50±2.27)%,(56.43±3.12)%,(61.87±3.46)%。低、高剂量联合组分别与rAd-p53低、高剂量组和DDP组比较,差异有统计学意义(P<0.05)。结论 rAd-p53可显著诱导SGC-7901细胞周期阻滞。Objective To explore the effect of recombinant adenovirs encoding human p53(rAd-p53) alone or in combination with cisplatin(DDP) on the human gastric cancinoma SGC-7901 cell cycle.Methods The human gastric cancinoma SGC-7901 cells were randomly divided into control group and rAd-p53 low-/high-dose group(5×10^8, 5×10^10 vp·mL^-1), the DDP group(2.5 mg·L^-1), low-/high-dose combination group(5×10^8 vp·mL^-1+2.5 mg·L^-1,5×10^10 vp·mL^-1+2.5 mg·L^-1). At 48 h after treatment, the cell cycle was analyzed by flow cytometry, The expressions of KAI1/CD82 and p53 were detected by immunocytochemistry. Results the ratio of cells arrestingin the G0/G1 phase in control group,the rAd-p53 low-/high-dose group,the DDP group, the low-/high-dose combination group were(32.07±1.45)%,(40.18±1.36)%,(44.64±1.27)%,(43.41±2.08)%,(49.56±1.12)%,(54.72±6.07)%;the expression of KAI1/CD82 proteins were(24.60±3.73)%,(32.73±3.15)% ( 35. 50 ± 2. 27) %,( 36. 13 ± 3. 77) %,( 48. 67 ± 4. 70) %,( 51. 70 ± 2. 55) %;the expression of p53 proteins were( 14. 60 ± 3. 63) %,( 43. 30 ± 2. 35) %,( 46. 40 ± 1. 80) %,( 49. 50 ± 2. 27) %,( 56. 43 ± 3. 12) %,( 61. 87 ± 3. 46) %. There were statistically significant differences between low-/high-dose combination group and the rA d-p53 low-/high-dose group/DDP group( P < 0. 05). Pearson correlation analysis showed that expressions of KAI1/CD82 and P53 were positive related. Conclusion rA d-p53 can induce cell cycle arrest of SGC-7901 cells by up-regulating the expressions of KAI1/CD82 and P53 proteins.

关 键 词：重组人P53腺病毒注射液 胃癌 细胞周期 

分 类 号：R97[医药卫生—药品]